Treats Alzheimer’s disease. Sold as Leqembi, Leqembi Iqlik. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Lecanemab-Irmb (sold as Leqembi, Leqembi Iqlik), first approved Jan 6, 2023, with 3 new uses approved and 0 published complete response letters.
| Leqembi | Part B | $195M | +115% | 14,029 |
| Leqembi | Part D | $906K | +76% | 78 |
| Leqembi Iqlik | Part D | $640K | New | 222 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's DiseaseAlzheimer's Disease · Eisai Inc. | — | Recruiting | Sep 16, 2026 |
| Jan 6, 2023 | LeqembiBLA 761269 · New molecular entity | Eisai Inc | 7 | Marketed |
| Aug 29, 2025 | Leqembi IqlikBLA 761375 · New dosage form | Eisai Inc | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
